4BIO portfolio company Orchard Therapeutics announces ADA-SCID follow-on results

Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID. 100% overall survival and 100% event free survival in patients treated with OTL-101 compared to 88% OS and 56% EvFS with historical HSCT overall at 24 months. Biologics License Application Submission Planned for the U.S. Read more at the company website.